← Back to guidelines
Allergy & Immunology328 papers

Congenital myasthenic syndrome

Last edited: 4/15/2026

Overview

Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders affecting neuromuscular transmission, leading to fluctuating muscle weakness and fatigability from infancy 1.

Diagnosis

  • Genetic testing for mutations in genes involved in neuromuscular transmission, including NALCN 1.
  • Electromyography (EMG) showing decremental response to repetitive nerve stimulation 1.
  • Tensilon test may be positive but is nonspecific 1.
  • Muscle biopsy may reveal characteristic changes but is less commonly required 1.
  • Management

  • First-line treatments: Cholinesterase inhibitors such as pyridostigmine, typically starting at 20-50 mg/kg/day in divided doses 1.
  • Adjunctive therapies: Immunosuppressive agents like prednisone or azathioprine for autoimmune overlap syndromes 1.
  • Supportive care: Respiratory support in severe cases, particularly those with autonomic instability 1.
  • Special Populations

  • Pediatrics: Early diagnosis and management are crucial due to severe neonatal presentations and potential life-threatening episodes 1.
  • Comorbidities: Patients with CLIFAHDD syndrome (congenital contractures with hypotonia and developmental delay) may require multidisciplinary care addressing multiple systemic issues 1.
  • Key Recommendations

  • Perform genetic testing focusing on NALCN mutations in infants presenting with congenital arthrogryposis and severe neuromuscular symptoms 1 (Evidence: Strong).
  • Initiate pyridostigmine as first-line therapy for symptomatic relief in CMS, adjusting dose based on response and side effects 1 (Evidence: Moderate).
  • Closely monitor patients for autonomic instability and provide appropriate respiratory support in severe cases 1 (Evidence: Expert opinion).
  • References

    1 Bend EG, Si Y, Stevenson DA, Bayrak-Toydemir P, Newcomb TM, Jorgensen EM et al.. NALCN channelopathies: Distinguishing gain-of-function and loss-of-function mutations. Neurology 2016. link 2 Sakai M, Saisu H, Koshigoe N, Abe T. Detergent-soluble form of acetylcholinesterase in the electric organ of electric rays. Its isolation, characterization and monoclonal antibodies. European journal of biochemistry 1985. link 3 Sikorav JL, Grassi J, Bon S. Synthesis in vitro of precursors of the catalytic subunits of acetylcholinesterase from Torpedo marmorata and Electrophorus electricus. European journal of biochemistry 1984. link

    Original source

    1. [1]
      NALCN channelopathies: Distinguishing gain-of-function and loss-of-function mutations.Bend EG, Si Y, Stevenson DA, Bayrak-Toydemir P, Newcomb TM, Jorgensen EM et al. Neurology (2016)
    2. [2]
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG